ジェノバ’s ordinary income for the fiscal year ended September 2026 came in at ¥808 million, up 3.3%. This was 1.9% above the prior forecast of ¥793 million, and the company forecast ordinary income of ¥839 million for the fiscal year ending September 2027.
ジェノバ reported ordinary income of ¥808 million for the fiscal year ended September 2026, an increase of 3.3% from the previous fiscal year. This was above the level anticipated by the company at the time of the announcement, and the full-year earnings forecast released on the same day is also expected to maintain this upward trend.
The forecast for ordinary income for the fiscal year ending September 2027 is ¥839 million, representing a projected increase of 3.8% at this stage. Ordinary income for the interim period is forecast at ¥433 million.
This earnings summary may attract investor attention as an indicator of future earnings trends. The article does not include comparisons with other companies or additional numerical support.